Cortexyme, Inc.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$1.36
FAIR PRICE
$0.20
MARGIN
$1.16
P/E Ratio
N/A
Div. Yield
N/A
ROE
7743.6%
Exceptional
Market Cap
$8M
Small-cap
FPI RATING
Low debt levels, but below-average fundamental quality and volatile earnings pattern.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$0.16
Fair price × 0.80
DISTANCE
88.2%
Price to entry level
At the current price of $1.36, QNCX trades 88.2% above the conservative entry level of $0.16. This entry level represents a 20% margin of safety below the calculated fair price of $0.20 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
COMING SOON
Get notified when QNCX's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Dirk Thye
COUNTRY
US
HEADQUARTERS
South San Francisco
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate QNCX's fair price
Cortexyme, Inc.'s fair price of $0.20 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $1.36, QNCX trades 85.3% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting QNCX's risk profile.
RELATIVE · 30%
Comparing QNCX's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for QNCX, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate QNCX's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for QNCX.
Explore on BuliosFAQ
What is the fair price of QNCX?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Cortexyme, Inc. is $0.20. At the current market price of $1.36, QNCX trades 85.3% above its calculated fair value.
Is QNCX overvalued or undervalued?+
Cortexyme, Inc. is currently overvalued based on our valuation model. The stock trades at $1.36, which is 85.3% above the fair price of $0.20.
What is the margin of safety for QNCX?+
With a 20% margin of safety applied to the fair price of $0.20, the conservative entry level for QNCX is $0.16. At the current market price of $1.36, the stock trades 88.2% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is QNCX's fair price updated?+
We update fair price calculations for QNCX daily after market close. The current fair price of $0.20 incorporates the latest market data and sector multiples.
What factors affect QNCX's fair price calculation?+
QNCX's fair price of $0.20 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 7743.6%.
Is QNCX a good buy right now?+
At $1.36, QNCX trades 85.3% above our fair value estimate of $0.20. The stock is currently overvalued. ROE stands at 7743.6% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does QNCX pay dividends?+
QNCX does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.